Sarah J. Freemantle
Papers
1
Total Citations
49
H-Index
1
About
Dr. Sarah J. Freemantle is a leading cancer biologist whose work has fundamentally advanced our understanding of cell cycle regulation and targeted therapy, particularly in lung cancer. Her research focuses on the mechanisms of anaphase catastrophe—a novel form of cell death triggered by aberrant mitosis—and the development of next-generation cyclin-dependent kinase (CDK) inhibitors. In her landmark 2016 study, Dr. Freemantle investigated CCT68127, a potent CDK2/9 inhibitor, demonstrating its superior ability to induce multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes. This work, which has garnered nearly 50 citations, built upon earlier findings with first-generation agents like seliciclib, establishing a critical link between CDK inhibition and mitotic catastrophe. Her contributions have provided a mechanistic blueprint for designing more selective, less toxic therapies that exploit centrosome amplification—a common vulnerability in aggressive tumors. Dr. Freemantle’s research continues to shape the landscape of precision oncology, offering new hope for patients with drug-resistant lung cancers.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016